VWM
KYMR icon

Vermillion Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Vermillion Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$83 – 2024
2026
Q1 		$83 Buy
+1
New +$79 ﹤0.01% 1463

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vermillion Wealth Management's KYMR Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 1 share — an estimated $83 sold.

Vermillion Wealth Management first reported a position in KYMR in Q1 2026 and held it in 1 quarter. The position peaked at $83 in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 1 Kymera Therapeutics share in Q2 2026, an estimated $83.
  • Vermillion Wealth Management first reported a position in Kymera Therapeutics in Q1 2026 and held it in 1 quarter.
  • Vermillion Wealth Management's Kymera Therapeutics position peaked at $83 in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.